G:NYSEGenpact Limited Analysis

Genpact posted a solid 6.7% YoY revenue increase to $1.30 bn and beat earnings estimates, but its forward revenue guidance fell short of consensus, triggering a 7.5% share‑price drop. Valuation metrics are compelling: the stock trades around $32, well below the DCF fair value of $69 and a PE of ~10 versus an industry average of ~43, offering roughly 30% upside. The dividend yield of 2.27% with a modest 21% payout ratio appears sustainable given strong operating cash flow and a healthy balance sheet.
Technical indicators signal short‑term pressure – the price sits beneath the 20‑day (31.9), 50‑day (34.3) and 200‑day (40.6) SMAs, RSI is near 47, and the MACD line is negative though the histogram is positive. A bearish trend, high 30‑day volatility (~46%), decreasing volume and a support level at $28.78 suggest caution, while the low beta (0.65) tempers market‑wide risk.